Mercer Global Advisors Inc. ADV Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Mercer Global Advisors Inc. ADV bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 66,269 shares of the company's stock, valued at approximately $803,000.

Other large investors also recently modified their holdings of the company. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health during the 3rd quarter valued at about $35,000. Jones Financial Companies Lllp grew its holdings in shares of Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares during the last quarter. SRS Capital Advisors Inc. raised its position in shares of Elanco Animal Health by 221.2% during the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares during the period. MRP Capital Investments LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $61,000. Finally, Blue Trust Inc. boosted its position in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Price Performance

NYSE ELAN opened at $12.02 on Friday. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80. The firm has a market capitalization of $5.97 billion, a PE ratio of 30.05, a P/E/G ratio of 2.50 and a beta of 1.49. The company's 50 day simple moving average is $9.89 and its 200 day simple moving average is $11.42. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 1.0% on a year-over-year basis. During the same period last year, the firm earned $0.34 EPS. As a group, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on ELAN. Morgan Stanley cut their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research note on Wednesday, February 26th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research note on Wednesday, February 26th. Piper Sandler dropped their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $13.00 to $15.00 and gave the stock a "buy" rating in a research report on Thursday. Finally, Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Elanco Animal Health currently has a consensus rating of "Hold" and an average target price of $15.00.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm's stock in a transaction on Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares in the company, valued at $1,136,881.80. This represents a 9.86 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.89% of the stock is owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.